RT Journal Article SR Electronic T1 Integrating de novo and inherited variants in over 42,607 autism cases identifies mutations in new moderate risk genes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.10.08.21264256 DO 10.1101/2021.10.08.21264256 A1 Xueya Zhou A1 Pamela Feliciano A1 Tianyun Wang A1 Irina Astrovskaya A1 Chang Shu A1 Jacob B. Hall A1 Joseph U. Obiajulu A1 Jessica Wright A1 Shwetha Murali A1 Simon Xuming Xu A1 Leo Brueggeman A1 Taylor R. Thomas A1 Olena Marchenko A1 Christopher Fleisch A1 Sarah D. Barns A1 LeeAnne Green Snyder A1 Bing Han A1 Timothy S. Chang A1 Tychele N. Turner A1 William Harvey A1 Andrew Nishida A1 Brian J. O’Roak A1 Daniel H. Geschwind A1 The SPARK Consortium A1 Jacob J. Michaelson A1 Natalia Volfovsky A1 Evan E. Eichler A1 Yufeng Shen A1 Wendy K. Chung YR 2021 UL http://medrxiv.org/content/early/2021/10/11/2021.10.08.21264256.abstract AB Despite the known heritable nature of autism spectrum disorder (ASD), studies have primarily identified risk genes with de novo variants (DNVs). To capture the full spectrum of ASD genetic risk, we performed a two-stage analysis of rare de novo and inherited coding variants in 42,607 ASD cases, including 35,130 new cases recruited online by SPARK. In the first stage, we analyzed 19,843 cases with one or both biological parents and found that known ASD or neurodevelopmental disorder (NDD) risk genes explain nearly 70% of the genetic burden conferred by DNVs. In contrast, less than 20% of genetic risk conferred by rare inherited loss-of-function (LoF) variants are explained by known ASD/NDD genes. We selected 404 genes based on the first stage of analysis and performed a meta-analysis with an additional 22,764 cases and 236,000 population controls. We identified 60 genes with exome-wide significance (p < 2.5e-6), including five new risk genes (NAV3, ITSN1, MARK2, SCAF1, and HNRNPUL2). The association of NAV3 with ASD risk is entirely driven by rare inherited LoFs variants, with an average relative risk of 4, consistent with moderate effect. ASD individuals with LoF variants in the four moderate risk genes (NAV3, ITSN1, SCAF1, and HNRNPUL2, n = 95) have less cognitive impairment compared to 129 ASD individuals with LoF variants in well-established, highly penetrant ASD risk genes (CHD8, SCN2A, ADNP, FOXP1, SHANK3) (59% vs. 88%, p= 1.9e-06). These findings will guide future gene discovery efforts and suggest that much larger numbers of ASD cases and controls are needed to identify additional genes that confer moderate risk of ASD through rare, inherited variants.Competing Interest StatementD.H.G. has received research funding from Takeda Pharmaceuticals, and consulting fees or equity participation for scientific advisory board work from Ovid Therapeutics, Axial Bio-therapeutics, Acurastem, and Falcon Computing. E.E.E. is on the Scientific Advisory Board (SAB) of DNAnexus, Inc. M.Sahin has received research funding from Novartis, Roche, Biogen, Astellas, Aeovian, Bridgebio, Aucta and Quadrant Biosciences and has served on Scientific Advisory Boards for Roche, Celgene, Regenxbio and Takeda. W.K.C. serves on the Regeneron Genetics Center Scientific Advisory Board and is the Director of Clinical Research for SFARI. A.D.K. is an employee of PreventionGenetics and a member of PrevGen Employees LLC, which owns units in PreventionGenetics. Z.E.W. serves as a consultant for Roche and receive research support from Adaptive Technology Consulting. All other authors declare no competing interests.Funding StatementFunding sources include the Simons Foundation Autism Research Initiative, HHMI and the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SPARK study is a multi-site study governed under a central IRB, Western IRB. The protocol name is: SPARK: Simons Foundation Powering Autism Research for Knowledge, a national cohort of individuals and families affected by Autism Spectrum Disorder. The protocol is updated and reviewed yearly. The current IRB tracking number at Western IRB is 20151664. The PI of the study is Wendy Chung.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in this manuscript is currently available to qualified researchers at base.sfari.org https://base.sfari.org/